Related Experiment Video
Updated: May 27, 2026
09:21
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Advances in pediatric rhabdomyosarcoma characterization and disease model development
D O'Brien1, A G Jacob, S J Qualman
1The Center for Childhood Cancer, Columbus Children's Research Institute and the Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
Histology and Histopathology
|December 1, 2011
Summary
Rhabdomyosarcoma (RMS), a pediatric cancer, involves complex genetic changes. Recent advancements in characterization and animal models offer new therapeutic avenues for this challenging soft tissue sarcoma.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Soft Tissue Sarcoma
Background:
- Rhabdomyosarcoma (RMS) is a prevalent pediatric malignancy with complex subtypes.
- Characterized by signaling pathway perturbations and genetic abnormalities, RMS requires risk stratification for treatment.
- Despite improved survival rates, highly invasive and metastatic forms remain challenging.
Purpose of the Study:
- To review key developments in Rhabdomyosarcoma characterization.
- To summarize advancements in in vivo model generation for RMS research.
- To highlight progress in understanding and modeling pediatric soft tissue sarcoma.
Main Methods:
- Review of clinical studies and research findings over recent decades.
- Analysis of genetic abnormalities and signaling pathway perturbations in RMS.
- Evaluation of genetically modified and tumor xenograft animal models for RMS.
Main Results:
- Classification of RMS into high and low-risk groups has refined treatment strategies.
- Identification of numerous potential therapeutic intervention points.
- Development of diverse in vivo models for preclinical testing.
Conclusions:
- Significant progress has been made in understanding and modeling Rhabdomyosarcoma.
- In vivo models are crucial for testing novel therapeutic strategies.
- Further research is needed to address metastatic and invasive RMS forms.
